The New England journal of medicine, 2021-12, Vol.385 (25), p.2313-2324
- Singh, Ajay K
- Carroll, Kevin
- McMurray, John J.V
- Solomon, Scott
- Jha, Vivekanand
- Johansen, Kirsten L
- Lopes, Renato D
- Macdougall, Iain C
- Obrador, Gregorio T
- Waikar, Sushrut S
- Wanner, Christoph
- Wheeler, David C
- Więcek, Andrzej
- Blackorby, Allison
- Cizman, Borut
- Cobitz, Alexander R
- Davies, Rich
- DiMino, Tara L
- Kler, Lata
- Meadowcroft, Amy M
- Taft, Lin
- Perkovic, Vlado
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Singh, Ajay K
- Carroll, Kevin
- McMurray, John J.V
- Solomon, Scott
- Jha, Vivekanand
- Johansen, Kirsten L
- Lopes, Renato D
- Macdougall, Iain C
- Obrador, Gregorio T
- Waikar, Sushrut S
- Wanner, Christoph
- Wheeler, David C
- Więcek, Andrzej
- Blackorby, Allison
- Cizman, Borut
- Cobitz, Alexander R
- Davies, Rich
- DiMino, Tara L
- Kler, Lata
- Meadowcroft, Amy M
- Taft, Lin
- Perkovic, Vlado
- Titel
- Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
- Ist Teil von
- The New England journal of medicine, 2021-12, Vol.385 (25), p.2313-2324
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- Electronic Journals Library
- Beschreibungen/Notizen
- This randomized trial compared daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, with darbepoetin alfa for the treatment of anemia in patients with chronic kidney disease who were not undergoing dialysis. Daprodustat was noninferior to darbepoetin alfa with respect to the change in hemoglobin level and cardiovascular outcomes.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2113380Titel-ID: cdi_hal_primary_oai_HAL_hal_03646895v1
- Format
- –
- Schlagworte
- Aged, Anemia, Anemia - drug therapy, Anemia - etiology, Barbiturates, Barbiturates - adverse effects, Barbiturates - therapeutic use, Cardiology, Cardiovascular Diseases, Cardiovascular Diseases - epidemiology, Cardiovascular Diseases - etiology, Cardiovascular Diseases - mortality, Cerebral infarction, Chronic Kidney Disease, Coronary Disease, COVID-19, Darbepoetin alfa, Darbepoetin alfa - adverse effects, Darbepoetin alfa - therapeutic use, Dialysis, Erythropoiesis, Female, Glycine, Glycine - adverse effects, Glycine - analogs & derivatives, Glycine - therapeutic use, Heart attacks, Hematinics, Hematinics - adverse effects, Hematinics - therapeutic use, Hematology, Hemodialysis, Hemoglobin, Hemoglobins, Hemoglobins - analysis, Human health and pathology, Humans, Hydroxylase, Hypoxia, Hypoxia-Inducible Factor-Proline Dioxygenases, Hypoxia-Inducible Factor-Proline Dioxygenases - antagonists & inhibitors, Hypoxia-inducible factors, Intention to Treat Analysis, Iron, Kidney diseases, Life Sciences, Male, Middle Aged, Myocardial Infarction, Myocardial Infarction - epidemiology, Nephrology, Oncology, Oncology General, Patients, Prolyl hydroxylase, Renal Insufficiency, Chronic, Renal Insufficiency, Chronic - blood, Renal Insufficiency, Chronic - complications, Software, Statistical analysis, Stroke, Stroke - epidemiology